Siemens Healthineers Hits Fresh Low as Qiagen Warning and Parent's Rally Create a Tale of Two Stocks

Siemens Healthineers hits 12-month low at €35.43, down 29% from 2025 peak, as medtech sector sentiment weakens. RSI at 31.6 signals oversold conditions, with analysts seeing 50% upside to €53 target.

The medical technology group Siemens Healthineers closed at €35.43 on Tuesday, marking its weakest level in twelve months and extending a losing streak to six consecutive sessions. The stock has now shed roughly 29 percent since hitting a 2025 high of €49.86 in July, with the year-to-date decline exceeding 20 percent.

The sell-off has pushed the relative strength index to 31.6, deep into oversold territory. Market participants are now watching the psychologically significant €35 threshold as a potential floor, though the 200-day moving average at €43.72 sits nearly 19 percent above the current price — a gap that underscores the severity of the recent downturn.

Sentiment across the medtech sector took an additional hit on Tuesday after Qiagen slashed its full-year forecasts for revenue growth and earnings per share, citing subdued expectations for the US biotech market and weaker demand in laboratory diagnostics. Qiagen shares briefly plunged almost 11 percent. While Siemens Healthineers has a more diversified business model, the broader anxiety has spilled over onto the stock.

The contrast with parent company Siemens could hardly be starker. Siemens shares rose roughly 1.0 percent to €254.35, hitting a three-month high. Investors are pricing in the planned full spin-off of the medical technology subsidiary, a decision slated for a vote at the annual general meeting in February 2027. The strategic realignment is widely viewed as a catalyst for unlocking value in Siemens' remaining industrial technology portfolio — but for Healthineers itself, a similar catalyst remains conspicuously absent.

Technology Pipeline Offers Little Respite

Despite the share price weakness, the company has been active on the product front. At the DMEA trade fair in Berlin in late April, Siemens Healthineers showcased solutions aimed at tackling healthcare workforce shortages, including the "syngo Virtual Cockpit" for remote access to scanning systems and the "Noona" platform for coordinated patient care. A separate market report from Black Book Research highlighted the company as a strategically important partner in Finland's healthcare market, one of Europe's most digitally advanced.

On the hardware side, the company recently received FDA clearance for its "Magnetom Flow" MRI platform. The 1.5-tesla system is designed to cut energy consumption by up to 56 percent compared with earlier models. Siemens Healthineers also introduced new angiography systems from the Artis series, which use AI-powered image processing to deliver higher image quality without increasing radiation dose.

Analysts see substantial upside from current levels. The average price target stands at €53.06, implying a potential gain of roughly 50 percent from Tuesday's close. For the current fiscal year, the company has proposed a dividend of €1.01 per share, marginally higher than the prior year.

Earnings Season Looms Large

The next major test arrives on May 7, when Siemens Healthineers publishes second-quarter results at 7:00 am CEST, followed by a press conference half an hour later. The numbers come at an awkward moment: the stock is trading about 19 percent below its 200-day moving average, and market sentiment is fragile.

First-quarter results for fiscal 2026 painted a mixed picture. Revenue rose four percent to €5.4 billion, but adjusted earnings per share came in at €0.49, down three percent year-on-year. For the full year, analysts expect EPS of €2.29. Whether the Q2 figures can arrest the downward trend will depend heavily on how management addresses the headwinds in the diagnostics business — the same segment that triggered Qiagen's profit warning and continues to weigh on the entire medtech space.